-
Professor Junfang Yang: Clinical Research and Practice of CD7 CAR-T Therapy in Relapsed/Refractory Hematologic Malignancies
On August 22–23, 2025, the 13th Lu Daopei Hematology Conference was held in Beijing, co-hosted by the Beijing Health Promotion Association and the Guangzhou Hongmian Oncology & Rare Disease Public…
-
2025 COMB丨Professor Peng Yuan: Multi-Gene Testing Drives Personalized Treatment and Illuminates a New Era in Precision Breast Cancer Care
Conference Highlights: From Detection to Treatment Oncology Frontier: The 8th COMB has opened successfully. Could you summarize the key themes and highlights of this year’s meeting? Professor Peng Yuan:The Conference…
-
Professor Ping Zhang at COMB 2025: Breaking Through Endocrine Resistance—New Precision Pathways for HR+/HER2- Breast Cancer
01 Oncology Frontier: To begin, could you outline the current situation regarding endocrine resistance in HR+/HER2- breast cancer? Professor Ping Zhang:Endocrine resistance in HR+/HER2- breast cancer can be divided into…
-
Academician Xishan Hao: The Mission of Advancing Chinese Oncology and Building Academic Journal
Oncology Frontier: Having witnessed the evolution of oncology research in China, how do you view the past, present, and future of this discipline? Academician Xishan Hao:Oncology is both an ancient…
-
Professor Xiaowei Qi: Preferred Neoadjuvant Strategies in HER2-Positive Breast Cancer and Breakthrough Directions in TNBC Immunotherapy
TCbHP as the Preferred Neoadjuvant Strategy in HER2-Positive Breast Cancer Oncology Frontier:In the debate on “optimal neoadjuvant strategies for HER2-positive breast cancer,” you supported the TCbHP regimen. Could you explain…
Connecting Medical Expertise through Media